ClinicalTrials.gg
CompletedNCT02766608telosUpdated Sep 24, 2019Results posted

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

A Phase 3 interventional study of BFF MDI 320/9.6 μg and BFF MDI 160/9.6 μg in Chronic Obstructive Pulmonary Disorder, sponsored by Pearl Therapeutics, Inc.. Completed at 260 sites in 8 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,389
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.

Enrollment
3rd of 43
2,389 · median 99
Started
2016
with 3 others
Phase 3
15 of 43
1 open now
Registered
28th of 43
by date
Lead sponsor
7 of 43
Pearl Therapeutics, Inc.

Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 3rd largest by enrollment, is one of 4 that started in 2016, is one of 15 in phase 3, and was the 28th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg) administered BID.

Read the detailed description

This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320 μg, and open-label Symbicort® TBH (200/6 μg) administered BID. Subjects will undergo a 1- to 4-week Screening Period. Subjects who successfully complete the Screening Period will be to one of the following five treatment groups:BFF MDI 320/9.6 μg BID (N=660), BFF MDI 160/9.6 μg BID, FF MDI 9.6 μg BID, BD MDI 320 μg BID, Symbicort®, TBH 400/12 μg BID. Following randomization, subjects will enter the Treatment Period and undergo additional treatment visits over 24 weeks.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disorder

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Give their signed written to participate
  2. Are at least 40 years of age and no older than 80 years
  3. patients who are symptomatic
  4. Must be receiving one or more inhaled bronchodilators as maintenance therapy

Exclusion criteria

Exclusion Criteria:

  1. Current diagnosis of asthma,
  2. due to α1-Antitrypsin Deficiency
  3. Known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months
  4. Long-term-oxygen therapy (≥ 12 hours a day).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,389 participants (actual)

Study arms

  • Experimental
    BFF MDI 320/9.6 μg

    Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID

    Drug: BFF MDI 320/9.6 μg

  • Experimental
    BFF MDI 160/9.6 μg

    Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID

    Drug: BFF MDI 160/9.6 μg

  • Experimental
    FF MDI 9.6 μg

    Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID

    Drug: FF MDI 9.6 μg

  • Experimental
    BD MDI 320 μg

    Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID

    Drug: BD MDI 320 μg

  • Other
    Symbicort® TBH 400/12 μg

    Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID

    Drug: Symbicort® TBH 400/12 μg BID

Interventions

  • DrugBFF MDI 320/9.6 μg

    Drug pages: Budesonide · Formoterol

    Blinded Treatment

    Also known as: Budesonide and Formoterol Fumarate Inhalation Aerosol

  • DrugBFF MDI 160/9.6 μg

    Blinded Treatment

    Also known as: Budesonide and Formoterol Fumarate Inhalation Aerosol

  • DrugFF MDI 9.6 μg

    Blinded Treatment

    Also known as: Formoterol Fumarate Inhalation Aerosol

  • DrugBD MDI 320 μg

    Blinded Treatment

    Also known as: Budesonide Inhalation Aerosol

  • DrugSymbicort® TBH 400/12 μg BID

    Drug page: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol

    Open Label

    Also known as: Symbicort® Turbuhaler

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI)

    Change from baseline in morning pre-dose trough FEV1 (Forced expiratory volume in 1 second) at Week 24 (BFF MDI versus FF MDI)

    Time frame: at Week 24

  2. Change From Baseline in FEV1 AUC0-4 (BFF MDI vs BD MDI)

    Changes from baseline in FEV1 AUC0-4 were normalized by taking the area under the curve value and dividing by the length of time under consideration (usually 4 hours). This normalization represents a weighted average of the change from baseline in FEV1 over the 4-hour period.

    Time frame: at Week 24

Secondary outcomes

  1. Time to First Moderate or Severe COPD Exacerbation (BFF MDI vs FF MDI).

    Time to first moderate or severe COPD (Chronic Obstructive Pulmonary Disease) exacerbation (BFF MDI vs FF MDI).

    Time frame: over 24 Weeks (timepoints of 4, 12 & 20 weeks)

  2. Percentage of Subjects Achieving an MCID (Minimal Clinically Important Difference) of 4 Units or More in SGRQ at Week 24

    The SGRQ (St. George's Respiratory Questionnaire) is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of BFF MDI, FF MDI, BD MDI, \& Symbicort TBH on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.

    Time frame: at Week 24

  3. Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI vs BD MDI)

    Change from baseline in morning pre-dose trough FEV1(Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)

    Time frame: at Week 24

  4. Peak Change From Baseline in FEV1 at Week 24 (BFF MDI vs BD MDI)

    Peak change from baseline in FEV1 (Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)

    Time frame: at Week 24

  5. Change From Baseline in Average Daily Rescue Ventolin HFA Use Over 24 Weeks (BFF MDI vs BD MDI)

    Change from baseline in average daily rescue Ventolin HFA use over 24 weeks (BFF MDI vs BD MDI)

    Time frame: over 24 Weeks

  6. FEV1 on Day 1, 5 Minutes, Time to Onset of Action Determination

    Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

    Time frame: Day 1 - 5 Minutes

  7. FEV1 on Day 1, 15 Minutes, Time to Onset of Action Determination

    Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

    Time frame: Day 1 - 15 Minutes

  8. FEV1 on Day 1, 30 Minutes, Time to Onset of Action Determination

    Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

    Time frame: Day 1 - 30 Minutes

  9. FEV1 on Day 1, 1 Hour, Time to Onset of Action Determination

    Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

    Time frame: Day 1 - 1 Hour

  10. FEV1 on Day 1, 2 Hours, Time to Onset of Action Determination

    Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

    Time frame: Day 1 - 2 Hours

  11. FEV1 on Day 1, 4 Hours, Time to Onset of Action Determination

    Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

    Time frame: Day 1 - 4 Hours

Other outcomes

  1. Substudy: 12-hour PFT Endpoint FEV1 AUC0-12

    Substudy: 12-hour PFT (Pulmonary Function Test) endpoint FEV1 (Forced Expiratory Volume) AUC0-12 (Area under the Curve 0-12). Changes from baseline in FEV1 AUC0-12 were normalized by taking the area under the curve value and dividing by the length of time under consideration. This normalization represents a weighted average of the change from baseline in FEV1 over the 12-hour period.

    Time frame: at Week 12

07

Results

Posted Sep 24, 2019

Participant flow

This study randomized subjects at 244 study centers in 7 countries, from June 2016 and November 2017. The study period was scheduled to take up to approximately 30 weeks for each individual subject from the time of screening through the follow-up period.

Participant flow — Overall Study
MilestoneBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
Started655637644206219
Completed576567554169190
Not completed7970903729
Withdrew: Adverse event2722171312
Withdrew: Withdrawal by subject2120241310
Withdrew: Lack of efficacy16153282
Withdrew: Lost to follow-up63522
Withdrew: Physician decision32312
Withdrew: Protocol disc criteria33400
Withdrew: Protocol violation04401
Withdrew: Administrative reasons31100

Outcome measures

PrimaryChange From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI)

Change from baseline in morning pre-dose trough FEV1 (Forced expiratory volume in 1 second) at Week 24 (BFF MDI versus FF MDI)

Time frame:
at Week 24
Reported as:
Least squares mean · Liter
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI)
LiterBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μg
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI)0.036 (0.019 to 0.053)0.017 (0.000 to 0.034)-0.003 (-0.020 to 0.015)
PrimaryChange From Baseline in FEV1 AUC0-4 (BFF MDI vs BD MDI)

Changes from baseline in FEV1 AUC0-4 were normalized by taking the area under the curve value and dividing by the length of time under consideration (usually 4 hours). This normalization represents a weighted average of the change from baseline in FEV1 over the 4-hour period.

Time frame:
at Week 24
Reported as:
Least squares mean · Liter
Change From Baseline in FEV1 AUC0-4 (BFF MDI vs BD MDI)
LiterBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 ugBD MDI 320 ugSymbicort TBH 400/12 ug
Change From Baseline in FEV1 AUC0-4 (BFF MDI vs BD MDI)0.194 (0.177 to 0.212)0.179 (0.161 to 0.197)0.161 (0.143 to 0.179)0.022 (-0.011 to 0.054)0.187 (0.157 to 0.218)
SecondaryTime to First Moderate or Severe COPD Exacerbation (BFF MDI vs FF MDI).

Time to first moderate or severe COPD (Chronic Obstructive Pulmonary Disease) exacerbation (BFF MDI vs FF MDI).

Time frame:
over 24 Weeks (timepoints of 4, 12 & 20 weeks)
Reported as:
Number · Percentage of Participants
Time to First Moderate or Severe COPD Exacerbation (BFF MDI vs FF MDI).
Percentage of ParticipantsBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 ug
Percentage of Subjects to Exacerbate at 4 Weeks3.2 (2.1 to 4.9)3.3 (2.2 to 5.1)5.5 (4.0 to 7.6)7.0 (4.2 to 11.5)1.8 (0.7 to 4.8)
Percentage of Subjects to Exacerbate at 12 Weeks9.8 (7.7 to 12.4)9.9 (7.8 to 12.5)15.0 (12.4 to 18.1)14.9 (10.6 to 20.7)8.6 (5.5 to 13.3)
Percentage of Subjects to Exacerbate at 20 Weeks14.4 (11.9 to 17.4)18.5 (15.6 to 21.8)20.5 (17.5 to 23.9)17.7 (13.0 to 23.9)13.1 (9.2 to 18.6)
SecondaryPercentage of Subjects Achieving an MCID (Minimal Clinically Important Difference) of 4 Units or More in SGRQ at Week 24

The SGRQ (St. George's Respiratory Questionnaire) is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of BFF MDI, FF MDI, BD MDI, \& Symbicort TBH on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.

Time frame:
at Week 24
Reported as:
Number · Percentage of Subjects
Percentage of Subjects Achieving an MCID (Minimal Clinically Important Difference) of 4 Units or More in SGRQ at Week 24
Percentage of SubjectsBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
Percentage of Subjects Achieving an MCID (Minimal Clinically Important Difference) of 4 Units or More in SGRQ at Week 2448.1247.2241.5943.6253.78
SecondaryChange From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI vs BD MDI)

Change from baseline in morning pre-dose trough FEV1(Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)

Time frame:
at Week 24
Reported as:
Least squares mean · Liter
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI vs BD MDI)
LiterBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI vs BD MDI)0.036 (0.019 to 0.053)0.017 (0.000 to 0.034)-0.003 (-0.020 to 0.015)-0.028 (-0.060 to 0.003)0.039 (0.009 to 0.069)
SecondaryPeak Change From Baseline in FEV1 at Week 24 (BFF MDI vs BD MDI)

Peak change from baseline in FEV1 (Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)

Time frame:
at Week 24
Reported as:
Least squares mean · Liter
Peak Change From Baseline in FEV1 at Week 24 (BFF MDI vs BD MDI)
LiterBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
Peak Change From Baseline in FEV1 at Week 24 (BFF MDI vs BD MDI)0.272 (0.254 to 0.291)0.258 (0.239 to 0.276)0.243 (0.224 to 0.261)0.116 (0.082 to 0.150)0.267 (0.253 to 0.299)
SecondaryChange From Baseline in Average Daily Rescue Ventolin HFA Use Over 24 Weeks (BFF MDI vs BD MDI)

Change from baseline in average daily rescue Ventolin HFA use over 24 weeks (BFF MDI vs BD MDI)

Time frame:
over 24 Weeks
Reported as:
Least squares mean · Puffs per day
Change From Baseline in Average Daily Rescue Ventolin HFA Use Over 24 Weeks (BFF MDI vs BD MDI)
Puffs per dayBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
Change From Baseline in Average Daily Rescue Ventolin HFA Use Over 24 Weeks (BFF MDI vs BD MDI)-1.3 (-1.5 to -1.1)-1.3 (-1.4 to -1.1)-1.1 (-1.2 to -0.9)-0.6 (-0.9 to -0.3)-1.2 (-1.5 to -0.9)
SecondaryFEV1 on Day 1, 5 Minutes, Time to Onset of Action Determination

Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

Time frame:
Day 1 - 5 Minutes
Reported as:
Least squares mean · Liter
FEV1 on Day 1, 5 Minutes, Time to Onset of Action Determination
LiterBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
FEV1 on Day 1, 5 Minutes, Time to Onset of Action Determination0.157 (0.148 to 0.166)0.151 (0.142 to 0.161)0.160 (0.150 to 0.169)0.025 (0.009 to 0.041)0.131 (0.115 to 0.148)
SecondaryFEV1 on Day 1, 15 Minutes, Time to Onset of Action Determination

Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

Time frame:
Day 1 - 15 Minutes
Reported as:
Least squares mean · Liter
FEV1 on Day 1, 15 Minutes, Time to Onset of Action Determination
LiterBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
FEV1 on Day 1, 15 Minutes, Time to Onset of Action Determination0.190 (0.180 to 0.200)0.186 (0.176 to 0.196)0.201 (0.191 to 0.211)0.040 (0.022 to 0.058)0.167 (0.149 to 0.184)
SecondaryFEV1 on Day 1, 30 Minutes, Time to Onset of Action Determination

Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

Time frame:
Day 1 - 30 Minutes
Reported as:
Least squares mean · Liter
FEV1 on Day 1, 30 Minutes, Time to Onset of Action Determination
LiterBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
FEV1 on Day 1, 30 Minutes, Time to Onset of Action Determination0.207 (0.196 to 0.217)0.207 (0.196 to 0.218)0.215 (0.205 to 0.226)0.047 (0.028 to 0.066)0.190 (0.172 to 0.209)
SecondaryFEV1 on Day 1, 1 Hour, Time to Onset of Action Determination

Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

Time frame:
Day 1 - 1 Hour
Reported as:
Least squares mean · Liter
FEV1 on Day 1, 1 Hour, Time to Onset of Action Determination
LiterBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
FEV1 on Day 1, 1 Hour, Time to Onset of Action Determination0.225 (0.213 to 0.236)0.221 (0.210 to 0.233)0.236 (0.225 to 0.248)0.053 (0.033 to 0.073)0.211 (0.191 to 0.231)
SecondaryFEV1 on Day 1, 2 Hours, Time to Onset of Action Determination

Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

Time frame:
Day 1 - 2 Hours
Reported as:
Least squares mean · Liter
FEV1 on Day 1, 2 Hours, Time to Onset of Action Determination
LiterBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
FEV1 on Day 1, 2 Hours, Time to Onset of Action Determination0.253 (0.241 to 0.265)0.234 (0.222 to 0.247)0.244 (0.231 to 0.256)0.063 (0.042 to 0.085)0.221 (0.200 to 0.243)
SecondaryFEV1 on Day 1, 4 Hours, Time to Onset of Action Determination

Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.

Time frame:
Day 1 - 4 Hours
Reported as:
Least squares mean · Liter
FEV1 on Day 1, 4 Hours, Time to Onset of Action Determination
LiterBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
FEV1 on Day 1, 4 Hours, Time to Onset of Action Determination0.230 (0.216 to 0.243)0.215 (0.202 to 0.229)0.212 (0.199 to 0.226)0.073 (0.049 to 0.097)0.209 (0.186 to 0.232)
Other pre-specifiedSubstudy: 12-hour PFT Endpoint FEV1 AUC0-12

Substudy: 12-hour PFT (Pulmonary Function Test) endpoint FEV1 (Forced Expiratory Volume) AUC0-12 (Area under the Curve 0-12). Changes from baseline in FEV1 AUC0-12 were normalized by taking the area under the curve value and dividing by the length of time under consideration. This normalization represents a weighted average of the change from baseline in FEV1 over the 12-hour period.

Time frame:
at Week 12
Reported as:
Least squares mean · Liter
Substudy: 12-hour PFT Endpoint FEV1 AUC0-12
LiterBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μg
Substudy: 12-hour PFT Endpoint FEV1 AUC0-120.135 (0.107 to 0.163)0.124 (0.097 to 0.152)0.117 (0.089 to 0.145)0.024 (-0.028 to 0.075)

Adverse events

Collected over Adverse events were collected from the time the subject signed informed consent throughout the treatment period and up to 14 days following the last dose of study drug. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BFF MDI 320/9.6 μg3/655 (0.5%)42/655 (6.4%)240/655 (36.6%)
BFF MDI 160/9.6 μg2/637 (0.3%)45/637 (7.1%)201/637 (31.6%)
FF MDI 9.6 μg2/644 (0.3%)72/644 (11.2%)219/644 (34%)
BD MDI 320 μg0/206 (0%)15/206 (7.3%)75/206 (36.4%)
Symbicort TBH 400/12 μg2/219 (0.9%)20/219 (9.1%)57/219 (26%)
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders15/65510/63729/6442/2066/219
PneumoniaInfections and infestations4/6555/6376/6440/2063/219
Cardiac failure congestiveCardiac disorders1/6551/6371/6442/2061/219
Pancreatitis acuteGastrointestinal disorders0/6550/6370/6440/2062/219
Atrial fibrillationCardiac disorders1/6555/6372/6441/2060/219
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/6552/6374/6440/2061/219
Atrial flutterCardiac disorders1/6550/6371/6441/2060/219
Myocardial ischaemiaCardiac disorders0/6550/6371/6441/2060/219
Atrioventricular block completeCardiac disorders0/6551/6370/6441/2060/219
Coronary artery stenosisCardiac disorders0/6550/6370/6441/2060/219
Most frequent other events
Showing 10 of 16
Most frequent other events
EventBFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μg
NasopharyngitisInfections and infestations40/65540/63743/64417/20614/219
Chronic obstructive pulmonary diseaseInfections and infestations16/65510/63730/6442/2066/219
Upper respiratory tract infectionInfections and infestations25/65521/63720/6445/2063/219
Muscle spasmsMusculoskeletal and connective tissue disorders14/6556/6376/6440/2068/219
HypertensionVascular disorders14/65522/63715/6445/2064/219
CoughRespiratory, thoracic and mediastinal disorders7/65515/63715/6447/2060/219
DyspnoeaRespiratory, thoracic and mediastinal disorders12/65511/6379/6447/2063/219
HeadacheNervous system disorders19/6558/63715/6443/2061/219
Back painMusculoskeletal and connective tissue disorders18/65513/63718/6443/2062/219
Oral candidiasisInfections and infestations17/65514/6375/6443/2063/219

Baseline characteristics

The Modified Intent-To-Treat (mITT) Population is a subset of the ITT Population, and is defined as all subjects with post-randomization data obtained prior to discontinuation from treatment. The Intent-To-Treat (ITT) Population is defined as all subjects who were randomized to treatment and received any amount of the study treatment.

Age, Continuous
Age, Continuous(Years)BFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μgTotal
Mean64.2 ± 7.764.3 ± 7.664.1 ± 8.064.2 ± 7.465.3 ± 7.064.3 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)BFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μgTotal
Values listed are mITT population — Female2532602618178933
Values listed are mITT population — Male4023773831251411428
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μgTotal
Values listed are mITT population — Hispanic or Latino1618218669
Values listed are mITT population — Not Hispanic or Latino6376166231982122286
Values listed are mITT population — Unknown or Not Reported230016
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BFF MDI 320/9.6 μgBFF MDI 160/9.6 μgFF MDI 9.6 μgBD MDI 320 μgSymbicort TBH 400/12 μgTotal
Values listed are mITT population — American Indian or Alaska Native222006
Values listed are mITT population — Asian110013
Values listed are mITT population — Native Hawaiian or Other Pacific Islander000000
Values listed are mITT population — Black or African American1915209871
Values listed are mITT population — White6336196221972102281
Values listed are mITT population — More than one race000000
Values listed are mITT population — Unknown or Not Reported000000
08

Study locations

260 sites
  • Research Site
    Athens, Alabama 35611, United States
  • Research Site
    Birmingham, Alabama 35243, United States
  • Research Site
    Dothan, Alabama 36305, United States
  • Research Site
    Phoenix, Arizona 85006, United States
  • Research Site
    Phoenix, Arizona 85020, United States
  • Research Site
    Tucson, Arizona 85745, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Gold River, California 95670, United States
  • Research Site
    Palm Springs, California 92262, United States
  • Research Site
    Sacramento, California 95823, United States
  • Research Site
    San Diego, California 92120, United States
  • Research Site
    Boulder, Colorado 80301, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    Littleton, Colorado 80127, United States
  • Research Site
    Hamden, Connecticut 06517, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Hialeah, Florida 33016, United States
  • Research Site
    Miami, Florida 33134, United States
  • Research Site
    Miami, Florida 33175, United States
  • Research Site
    Miami, Florida 33186, United States
  • Research Site
    Panama City, Florida 32405, United States
  • Research Site
    Port Orange, Florida 32127, United States
  • Research Site
    Port Orange, Florida 32129, United States
  • Research Site
    Tampa, Florida 33603, United States
  • Research Site
    Winter Park, Florida 32789-4681, United States
  • Research Site
    Blue Ridge, Georgia 30513, United States
  • Research Site
    Meridian, Idaho 83646, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Westminster, Maryland 21157, United States
  • Research Site
    North Dartmouth, Massachusetts 02747, United States
  • Research Site
    Farmington Hills, Michigan 48336, United States
  • Research Site
    Edina, Minnesota 55435, United States
  • Research Site
    Fridley, Minnesota 55432, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Woodbury, Minnesota 55125, United States
  • Research Site
    Saint Charles, Missouri 63301, United States
  • Research Site
    Saint Louis, Missouri 63141, United States
  • Research Site
    Henderson, Nevada 89014, United States
  • Research Site
    Henderson, Nevada 89052, United States
  • Research Site
    Las Vegas, Nevada 89118, United States
  • Research Site
    Jackson Heights, New York 11236, United States
  • Research Site
    Larchmont, New York 10803, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Gastonia, North Carolina 28054, United States
  • Research Site
    Greensboro, North Carolina 27408, United States
  • Research Site
    Huntersville, North Carolina 28078, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Fargo, North Dakota 58103, United States
  • Research Site
    Columbus, Ohio 43213, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Dayton, Ohio 45459, United States
  • Research Site
    Dublin, Ohio 43016, United States
  • Research Site
    Grove City, Ohio 43123, United States
  • Research Site
    Oklahoma City, Oklahoma 73103, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Pittsburgh, Pennsylvania 15236, United States
  • Research Site
    Pittsburgh, Pennsylvania 15243, United States
  • Research Site
    Anderson, South Carolina 29621, United States
  • Research Site
    Easley, South Carolina 29640, United States
  • Research Site
    Gaffney, South Carolina 29341, United States
  • Research Site
    Greenville, South Carolina 29615, United States
  • Research Site
    Indian Land, South Carolina 29707, United States
  • Research Site
    Mount Pleasant, South Carolina 29464, United States
  • Research Site
    Rock Hill, South Carolina 29732, United States
  • Research Site
    Seneca, South Carolina 29678, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Union, South Carolina 29379, United States
  • Research Site
    Johnson City, Tennessee 37601, United States
  • Research Site
    Kingsport, Tennessee 37660, United States
  • Research Site
    Channelview, Texas 77530, United States
  • Research Site
    Live Oak, Texas 78233, United States
  • Research Site
    New Braunfels, Texas 78130, United States
  • Research Site
    San Antonio, Texas 78212, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Sugar Land, Texas 77479, United States
  • Research Site
    South Burlington, Vermont 05403, United States
  • Research Site
    Newport News, Virginia 23606, United States
  • Research Site
    Richmond, Virginia 23294, United States
  • Research Site
    Bellevue, Washington 98004, United States
  • Research Site
    Bellevue, Washington 98007, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Edmonton, Alberta T6L 5X8, Canada
  • Research Site
    Winnipeg, Manitoba R2K 3S8, Canada
  • Research Site
    Truro, Nova Scotia B2N 1L2, Canada
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Burlington, Ontario L7M 4Y1, Canada
  • Research Site
    Sudbury, Ontario P3A 1W8, Canada
  • Research Site
    Toronto, Ontario M3J 2C5, Canada
  • Research Site
    Windsor, Ontario N8X 1T3, Canada
  • Research Site
    Windsor, Ontario N8X 5A6, Canada
  • Research Site
    Mirabel, Quebec J7J 2K8, Canada
  • Research Site
    Montreal, Quebec H1M 1B1, Canada
  • Research Site
    Pointe-Claire, Quebec H9R 3J1, Canada
  • Research Site
    St Charles Borromee, Quebec J6E 2B4, Canada
  • Research Site
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Research Site
    Victoriaville, Quebec G6P 6P6, Canada
  • Research Site
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Research Site
    Quebec, G1G 3Y8, Canada

Showing the first 100 of 260 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Singh D, Hurst JR, Martinez FJ, Rabe KF, Bafadhel M, Jenkins M, Salazar D, Dorinsky P, Darken P. Predictive modeling of COPD exacerbation rates using baseline risk factors. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221107314. doi: 10.1177/17534666221107314. PubMed 35815359 ↗
  • Ferguson GT, Papi A, Anzueto A, Kerwin EM, Cappelletti C, Duncan EA, Nyberg J, Dorinsky P. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. Eur Respir J. 2018 Sep 16;52(3):1801334. doi: 10.1183/13993003.01334-2018. Print 2018 Sep. PubMed 30220648 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Dec 2017, 18 months.

Results were first posted in Sep 2019, 1 year 9 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 18 months is close to that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2016
First posted
May 10, 2016
StartActual
May 31, 2016
Primary completionActual
Dec 1, 2017
CompletionActual
Dec 1, 2017
Results first posted
Sep 24, 2019
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02766608
Responsible party
Sponsor
First posted
May 10, 2016
Start date
May 31, 2016
Primary completion
Dec 1, 2017
Completion
Dec 1, 2017
Results posted
Sep 24, 2019
Last update
Sep 24, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion